Rapid, sensitive and robust UHPLC-LC/MS/MS-screening for 60 drugs of abuse in oral fluids

Significance of the topic

Oral fluid testing has gained acceptance as a non-invasive, adulteration-resistant alternative to urine for workplace, clinical and forensic drug screening. Its utility is enhanced by chromatographic methods that detect parent drugs, metabolites and common adulterants in a single, streamlined assay.

Study objectives and overview

This study presents the development of a rapid, sensitive and cost-effective UHPLC-LC/MS/MS method for simultaneous screening of 60 drugs of abuse and their metabolites in oral fluids. The assay focuses on opiates and cocaine derivatives, including modern patterns of multi-drug and adulterant use such as “street” heroin and cocaine mixtures (“snow balls”).

Methodology

• Sample collection: Saliva was collected using a buffered pH 4.2 system and confirmed for authenticity via alpha-amylase immunoassay.
• Sample preparation: Addition of deuterated internal standards, protein precipitation with sulpho salicylic acid and acetonitrile, centrifugation, evaporation under nitrogen and reconstitution in aqueous/methanolic solvent.
• Chromatography: Nexera X2 UHPLC with a phenyl-phase column (1.7 µm, 2.1×150 mm), 6-minute gradient (15–100% methanol with 0.1% formic acid) at 0.65 mL/min and 60 °C.
• Mass spectrometry: Shimadzu LCMS-8050 operated in positive ESI mode, unit resolution on Q1/Q3 (0.7 Da FWHM), multiple reaction monitoring with five transitions per analyte, two transitions per deuterated standard.
• Calibration: Sixteen-point curves covering 0.05–20 ng/mL (adjusted per compound), achieving correlation coefficients r² ≥ 0.995.

Used Instrumentation

• Shimadzu Nexera X2 UHPLC system with SIL-30ACMP autosampler
• Shimadzu LCMS-8050 triple quadrupole mass spectrometer

Main results and discussion

• Complete separation and detection of 60 analytes in oral fluid within a 6 min run time.
• Excellent linearity across calibration ranges (r² ≥ 0.995).
• Successful identification of street heroin samples showing a characteristic fingerprint: 6-acetylmorphine, morphine, codeine, norcodeine, 6-acetylcodeine, cocaine and its hydrolysis products methylecgonine and benzoylecgonine.
• Robust monitoring of multi-drug consumption, adulterants and metabolic artefacts in a single assay.
• Matrix effects and cutoff thresholds effectively managed through deuterated standards and optimized sample preparation.

Benefits and practical applications

• Non-invasive, rapid screening suitable for workplace, clinical and forensic settings.
• High throughput enabled by a 6-minute analytical cycle supports large sample volumes.
• Comprehensive panel including parent drugs, metabolites and emerging psychoactive substances.
• Accurate quantitation and reproducibility ensured by deuterated internal standards.

Future trends and applications

Advances may include integration with high-resolution mass spectrometry for broader screening, automated sample handling for point-of-care use, expansion of target panels to novel psychoactive substances and application of data analytics for trend monitoring in public health and forensic investigations.

Conclusion

The presented UHPLC-LC/MS/MS method delivers a rapid, sensitive and robust approach for multi-analyte screening of drugs of abuse in oral fluids. It effectively addresses matrix challenges and supports comprehensive monitoring of modern drug use patterns.

References

1. M. Böttcher (2015). Oral fluid as an alternative matrix for monitoring licit and illicit drug abuse. Workshop Nal von Minden/Chiron “New Psychoactive Substances”, Munich.
2. Reisfield G.M. (2007). Ann Clin Lab Sci Autumn, 37(4), 301–314.
3. Böttcher M., Lierheimer S. (2012). Monitoring drug abuse of patients in substitution therapy: comparison of UPLC-MS/MS screening in oral fluid and urine testing with immunoassay. SOFT, Boston.
4. Böttcher M., Guenther N., Lierheimer S., Beck O. (2013). UPLC-MS/MS multi-target screening of 55 commonly abused drugs at different cutoffs in oral fluid from patients in addiction treatment. TIAFT Kongress, Madeira.